223 related articles for article (PubMed ID: 30656305)
1. Peptide ligand-mediated targeted drug delivery of nanomedicines.
Jiang Z; Guan J; Qian J; Zhan C
Biomater Sci; 2019 Jan; 7(2):461-471. PubMed ID: 30656305
[TBL] [Abstract][Full Text] [Related]
2. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
David A
Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
[TBL] [Abstract][Full Text] [Related]
3. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
[TBL] [Abstract][Full Text] [Related]
4. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
5. Heteromultivalent ligand-decoration for actively targeted nanomedicine.
Modery-Pawlowski CL; Gupta AS
Biomaterials; 2014 Mar; 35(9):2568-79. PubMed ID: 24411677
[TBL] [Abstract][Full Text] [Related]
6. Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers.
Raza F; Zafar H; You X; Khan A; Wu J; Ge L
J Mater Chem B; 2019 Dec; 7(48):7639-7655. PubMed ID: 31746934
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
[TBL] [Abstract][Full Text] [Related]
8. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine delivers promising treatments for rheumatoid arthritis.
Prasad LK; O'Mary H; Cui Z
Nanomedicine (Lond); 2015; 10(13):2063-74. PubMed ID: 26084368
[TBL] [Abstract][Full Text] [Related]
10. Modulating angiogenesis with integrin-targeted nanomedicines.
Duro-Castano A; Gallon E; Decker C; Vicent MJ
Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
[TBL] [Abstract][Full Text] [Related]
11. Aptamers and their applications in nanomedicine.
Sun H; Zu Y
Small; 2015 May; 11(20):2352-64. PubMed ID: 25677591
[TBL] [Abstract][Full Text] [Related]
12. The smart targeting of nanoparticles.
Friedman AD; Claypool SE; Liu R
Curr Pharm Des; 2013; 19(35):6315-29. PubMed ID: 23470005
[TBL] [Abstract][Full Text] [Related]
13. Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications.
Durymanov M; Kamaletdinova T; Lehmann SE; Reineke J
J Control Release; 2017 Sep; 261():10-22. PubMed ID: 28625673
[TBL] [Abstract][Full Text] [Related]
14. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
Jiang Z; Chu Y; Zhan C
Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
17. Peptide-decorated polymeric nanomedicines for precision cancer therapy.
Sun H; Dong Y; Feijen J; Zhong Z
J Control Release; 2018 Nov; 290():11-27. PubMed ID: 30290243
[TBL] [Abstract][Full Text] [Related]
18. The enhanced permeability retention effect: a new paradigm for drug targeting in infection.
Azzopardi EA; Ferguson EL; Thomas DW
J Antimicrob Chemother; 2013 Feb; 68(2):257-74. PubMed ID: 23054997
[TBL] [Abstract][Full Text] [Related]
19. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
Dhaliwal A; Zheng G
Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
[TBL] [Abstract][Full Text] [Related]
20. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
